EP1660636A4 - Anti-cancer vaccines - Google Patents

Anti-cancer vaccines

Info

Publication number
EP1660636A4
EP1660636A4 EP04782297A EP04782297A EP1660636A4 EP 1660636 A4 EP1660636 A4 EP 1660636A4 EP 04782297 A EP04782297 A EP 04782297A EP 04782297 A EP04782297 A EP 04782297A EP 1660636 A4 EP1660636 A4 EP 1660636A4
Authority
EP
European Patent Office
Prior art keywords
cancer vaccines
vaccines
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04782297A
Other languages
German (de)
French (fr)
Other versions
EP1660636A2 (en
Inventor
Jeffrey Molldrem
A John Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Texas System
Original Assignee
US Department of Health and Human Services
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Texas System filed Critical US Department of Health and Human Services
Publication of EP1660636A2 publication Critical patent/EP1660636A2/en
Publication of EP1660636A4 publication Critical patent/EP1660636A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04782297A 2003-08-26 2004-08-26 Anti-cancer vaccines Withdrawn EP1660636A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49823803P 2003-08-26 2003-08-26
PCT/US2004/027790 WO2005019435A2 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines

Publications (2)

Publication Number Publication Date
EP1660636A2 EP1660636A2 (en) 2006-05-31
EP1660636A4 true EP1660636A4 (en) 2009-07-01

Family

ID=34216164

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04782297A Withdrawn EP1660636A4 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
EP04809624A Withdrawn EP1670899A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04809624A Withdrawn EP1670899A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Country Status (5)

Country Link
EP (2) EP1660636A4 (en)
JP (1) JP2007504149A (en)
AU (1) AU2004267506A1 (en)
CA (1) CA2536654A1 (en)
WO (2) WO2005019435A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116423A2 (en) * 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110097312A1 (en) * 2008-02-15 2011-04-28 Board Of Regents, The University Of Texas System Anti-cancer vaccines
BRPI0913612B8 (en) 2008-06-05 2021-05-25 Immunovaccine Technologies Inc injectable vaccine composition, method of obtaining the composition and use of the composition
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN103961697A (en) * 2013-02-05 2014-08-06 日东电工株式会社 Vaccine composition for mucosal administration
KR20140100417A (en) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 Vaccine composition for transdermal administration
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6669401A (en) * 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOLLDREM J ET AL: "TARGETED T-CELL THERAPY FOR HUMAN LEUKEMIA: CYTOTOXIC T LYMPHOCYTESSPECIFIC FOR A PEPTIDE DERIVED FROM PROTEINASE 3 PREFERENTIALLY LYSE HUMAN MYELOID LEUKEMIA CELLS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 88, no. 7, 1 October 1996 (1996-10-01), pages 2450 - 2457, XP000884740, ISSN: 0006-4971 *
MOLLDREM J J ET AL: "Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 9, 1 September 2000 (2000-09-01), pages 1018 - 1023, XP002993663, ISSN: 1078-8956 *
MOLLDREM JEFFREY J ET AL: "Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 8, XP008106166, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2004267506A1 (en) 2005-03-03
WO2005035714A2 (en) 2005-04-21
WO2005019435A3 (en) 2006-06-29
WO2005019435A2 (en) 2005-03-03
JP2007504149A (en) 2007-03-01
CA2536654A1 (en) 2005-03-03
EP1670899A2 (en) 2006-06-21
WO2005019435A8 (en) 2006-04-27
EP1660636A2 (en) 2006-05-31
WO2005035714A3 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
TWI365191B (en) Vaccine
GB2434367B (en) Improved vaccines
IL178890A0 (en) Vaccines
EP1682173A4 (en) Listeria-based epha2 vaccines
EP1670509A4 (en) Multiplex vaccines
GB0409940D0 (en) Vaccine
EP1660636A4 (en) Anti-cancer vaccines
EP1732580A4 (en) Epha2 vaccines
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0420634D0 (en) Vaccines
GB0411150D0 (en) Vaccine
GB0323840D0 (en) Vaccines
GB0305794D0 (en) Vaccine
GB0321999D0 (en) Anti-cancer combinations
GB0330079D0 (en) Vaccine
GB0321614D0 (en) Vaccines
GB0305793D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0304634D0 (en) Vaccines
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
SI1523991T1 (en) Anti-cancer vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0419918D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060302

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/10 20060101ALI20060707BHEP

Ipc: A61K 39/00 20060101ALI20060707BHEP

Ipc: A61K 38/00 20060101AFI20060707BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 20060101AFI20070626BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/00 20060101ALI20090527BHEP

Ipc: A61P 35/02 20060101ALI20090527BHEP

Ipc: A61K 39/00 20060101AFI20090527BHEP

18W Application withdrawn

Effective date: 20090625